BEFORE THE ADVENT OF CIMETlDINE, antacids played a central role in the therapy of peptic ulcer disease. Many studies have appeared in the literature attempting to determine how much of what potency antacid should be given how often for maximal therapeutic response. Most studies on antacid therapy have concentrated on Iiquld preparations. It has been repeatedly stated in the literature that antacid tablets are not as effective as liquid antacids, and their use has been condemned by some authors.':" While this blanket statement appears to have been well accepted in the scientific community and is reiterated in several prominent texts,": a literature search reveals that such a conclusion for all antacid types may be unjustified.
In 1954, Bossett and Rice compared the in vitro antacid capability of equivalent amounts of aluminum hydroxide liquid with tablets, as well as a combination of magnesium and aluminum hydroxides. These investigators found the liquid antacids to be more effective neutralizers than the tablet forms of the same antacids. In contrast, they found the tablet form of dihydroxyaluminum aminoacetate to be more effective than any of the antacids tested, including its liquid form." Unfortunately, these investigators failed to state whether the tablets were crushed prior to placement in the in vitro testing system.
Lehman and Pollack also found liquid antacid preparations to be better neutralizers in vitro than tablet forms. These investigators did find that ground tablet preparations fared better than unground tablets, but still fell short of the neutralizing abilities of the liquid preparations: There is some question a~to whether or not these investigators used equivalent doses of the different antacid forms.
Ekenved and Walan utilized the Heidelberg Capsule technique to evaluate the in vivo neutralizing ability of four dosage forms of a combination of aluminum hydroxide and magnesium carbonate: a liquid preparation, a chewable tablet, and two tablet preparations designed to be swallowed whole. The Heidelberg Capsule is calibrated prior to the patient swallowing the capsule, and allows constant recording of pH. The capsule is attached to a string which allows the investigator to appropriately position the capsule in the stomach. Prior to in vivo studies, these investigators performed in vitro tests on all four preparations. Chewable tablets were crushed prior to in vitro tests, but the other two tablet preparations were added whole. Their in vitro results showed the liquid and chew-120 able tablet preparations to be equal in onset and duration of action, as well as in neutralizing potency. The "nonchewable" tablet preparations had a slower onset and lower neutralizing capacity. In vivo studies demonstrated that the liquid preparation and chewable tablet (which was thoroughly chewed by the subjects) were equal in efficacy.' Unfortunately, interpretation of these results is hampered by the fact that the liquid preparation apparently contained some magnesium hydroxide as well as magnesium carbonate and aluminum hydroxide. The tablet preparations did not contain magnesium hydroxide.
Smyth evaluated the in vitro and in vivo neutralizing ability of a combination of magnesium hydroxide, aluminum hydroxide, and calcium carbonate in tablet and liquid form. In vitro tests showed there was no significant difference between tablets (which were crushed) and suspensions in time to reach pH greater than 3, time above pH3, and maximum pH reached. Fasting and post-cibal in vivo tests also found no significant difference between the chewed tablet and the suspension.· Brouwers and Tytgat studied three liquid and tablet antacid preparations in vitro and in vivo; aluminum hydroxide, aluminum hydroxide/magnesium carbonate, and hydrotalcite. Tablets were crushed for in vitro studies and thoroughly chewed by subjects for the in vivo studies. Equivalent doses of aluminum hydroxide suspension were shown to have more neutralizing ability both in vitro and in vivo than the tablet form. In contrast, the aluminum hydroxide/magnesium carbonate suspension and tablets were equal in efficacy in both in vitro and in vivo tests. The hydrotalcite suspension and tablet were not significantly different in neutralizing ability in vitro, but the suspension proved to be far superior in vivo."
It can be seen from this discussion that results of studies are inconsistent as to the efficacy of antacid tablets. The more recent studies, which have included in vivo tests, indicate that antacid combination products may be just as efficacious in tablet as they are in liquid form -provided the tablets are thoroughly chewed. It appears, however, that aluminum hydroxide when used alone is not effective in a tablet form. This may be due to the drying process involved in manufacturing aluminum hydroxide tablets."
While it is not our purpose to advocate the substitution of antacid tablets for suspensions in the treatment of peptic ulcer disease, we do intend the foregoing discussion to enlighten clinicians regarding the effectiveness (or lack thereof) of antacid tablets, and to serve as an impetus for further research in this area. Clinicians with patients who insist on using antacid tablets rather than suspensions, despite their repeated objections, may take heart in knowing that their patients may not be receiving ineffective therapy. 
